RT Journal Article
SR Electronic
T1 Chinese medicine (Q-14) in the Treatment of Patients with Coronavirus Disease 2019 (COVID-19): A Single-center, Open label, Randomised Controlled Trial
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2021.01.25.21249417
DO 10.1101/2021.01.25.21249417
A1 Liu, Jia
A1 Yang, Wei
A1 Liu, Yue
A1 Lv, Cheng
A1 Ruan, Lianguo
A1 Zhao, Chen
A1 Huo, Ruili
A1 Shen, Xin
A1 Miao, Qing
A1 Lv, Wenliang
A1 Li, Hao
A1 Shi, Huaxin
A1 Hu, Lijie
A1 Yang, Zhixu
A1 Zhang, Li
A1 Wang, Bing
A1 Dong, Guoju
A1 Xian, Yongyue
A1 Li, Bin
A1 Zhou, Zhenqi
A1 Xu, Chunyan
A1 Chen, Yingying
A1 Bian, Yongjun
A1 Guo, Jing
A1 Yang, Jinliang
A1 Wang, Jian
A1 Qi, Wensheng
A1 Chen, Suping
A1 Chen, Yang
A1 Yan, Bei
A1 Wang, Wei
A1 Li, Jing
A1 Xie, Xiaolei
A1 Xu, Ming
A1 Jiang, Jianxin
A1 Wang, Gang
A1 Cong, Xiaodong
A1 Zhu, Haoning
A1 Shi, Jiaheng
A1 Leng, Luxing
A1 Li, Dongxu
A1 Guo, Lanping
A1 Huang, Luqi
YR 2021
UL http://medrxiv.org/content/early/2021/01/26/2021.01.25.21249417.abstract
AB OBJECTIVE To evaluate the efficacy and safety of Chinese medicine (Q-14) plus standard care compared with standard care alone in adult with coronavirus disease 2019 (COVID-19).Study DESIGN Single-center, open label, randomised controlled trial.SETTING Wuhan Jinyintan Hospital, Wuhan, China, February 27 to March 27, 2020.PARTICIPANTS 204 patients with laboratory confirmed COVID-19 were randomised in to treatment group and control group, which was 102 patients each group.INTERVENTIONS In treatment group, Q-14 was administrated at 10g (granules), twice daily for 14 days and plus standard care. In control group, patients were given standard care alone for 14 days.MAIN OUTCOME MEASURE The primary outcome was conversion time of SARS-CoV-2 viral assay. Adverse events were analyzed in the safety population.RESULTS Among 204 patients, 195 were analyzed according to the intention to treat principle. There were 149 patients (71 vs. 78 in treatment group and control group respectively) turning to negative via SARS-CoV-2 viral assay. No statistically significance showed in conversion time between treatment group and control group (FAS: Median (IQR): 10.00 (9.00-11.00) vs. 10.00 (9.00-11.00); Mean rank: 67.92 vs. 81.44; P=0.051.). Time to recovery of fever was shorter in treatment group as compared in control group. The disappearance rate of symptom in cough, fatigue, chest discomfort was significantly higher in treatment group. In chest computed tomography (Chest CT) examinations, overall evaluation of chest CT examination after treatment compared with baseline showed more patients improved in treatment group .There were no significant differences in the other outcomes.CONCLUSION Administration of Q-14 on standard care for COVID-19 was useful for improvement of symptoms (such as fever, cough, fatigue and chest discomfort), while did not result in a significantly higher probability of negative conversion of SARS-CoV-2 viral assay. No serious adverse events were reported.TRIAL REGISTRATION ChiCTR2000030288Competing Interest StatementThe authors have declared no competing interest.Clinical TrialChiCTR2000030288Funding StatementThe study was funded by National Key Research and Development Plan for the Emergency Management of Novel Coronavirus Pneumonia (No. 2020YFC0841500)Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The study protocol had been approved by the Ethics Review Committee of China Academy of Chinese Medical Sciences.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesResearch data was recorded using Medroad Cloud Electronic Data Capture System (Jiangsu Famous Medicine Science and Technology Ltd.) http://cloud.medroad.cn/CIConfidence intervalCNMTCM-CACMSChina National Medical Team of Traditional Chinese Medicine of China Academy of Chinese Medical SciencesCONSORTConsolidated Standards of Reporting TrialsCOVID-19Coronavirus Disease 2019CTComputed tomographyECMOExtracorporeal membrane oxygenationFASFull Analysis SetGCPGood Clinical PracticeIQRInterquartile rangeNHC-NATCM-China guidelinesNational clinical practice guideline for COVID-19 in China” developed by the National Health Commission and the National Administration of TCM of the People’s Republic of ChinaPPSPer-protocol SetRT-PCRReverse-transcription polymerase chain reactionSCIO-ChinaState Council Information Office of the People’s Republic of ChinaTCMTraditional Chinese medicineWHOWorld Health Organization